methyl 4-(3-fluoro-4-nitrophenoxy)pyridine-2-carboxylate | 864245-60-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: methyl 4-(3-fluoro-4-nitrophenoxy)pyridine-2-carboxylate
• 英文别名: methyl 4-(3-fluoro-4-nitrophenoxy)picolinate
• CAS: 864245-60-3
• 化学式: C₁₃H₉FN₂O₅
• 分子量: 292.223
• InChiKey: XZRAKSDGBWAWPH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  94.2
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  methyl 4-(3-fluoro-4-nitrophenoxy)pyridine-2-carboxylate 在 palladium 10% on activated carbon 氢气 作用下， 以 甲醇 为溶剂， 反应 4.5h， 生成 methyl 4-(4-amino-3-fluorophenoxy)picolinate
  参考文献：
  名称：

  Novel pyridine derivative and pyrimidine derivative

  摘要：

  以下化合物的分子式，其盐或前述水合物具有出色的肝细胞生长因子受体（HGFR）抑制活性，并表现出抗肿瘤活性、抑制血管生成活性和抑制癌转移活性。 [R 1 代表C 1-6 烷基或类似物；R 2 和R 3 代表氢；R 4 ，R 5 ，R 6 和R 7 可以相同也可以不同，每个代表氢、卤素、C 1-6 烷基或类似物；R 8 代表氢或类似物；R 9 代表C 1-6 烷基或类似物；V 1 代表氧或类似物；V 2 代表氧或硫；W代表—NH—或类似物；X代表—CH═、氮或类似物；Y代表氧或类似物。]

  公开号：

  US20050277652A1
• 作为产物：
  描述：

  4-氯吡啶-2-甲酸甲酯 、 3-氟-4-硝基苯酚 以 氯苯 为溶剂， 反应 2.33h， 以27.5%的产率得到methyl 4-(3-fluoro-4-nitrophenoxy)pyridine-2-carboxylate
  参考文献：
  名称：

  Novel pyridine derivative and pyrimidine derivative

  摘要：

  以下化合物的分子式，其盐或前述水合物具有出色的肝细胞生长因子受体（HGFR）抑制活性，并表现出抗肿瘤活性、抑制血管生成活性和抑制癌转移活性。 [R 1 代表C 1-6 烷基或类似物；R 2 和R 3 代表氢；R 4 ，R 5 ，R 6 和R 7 可以相同也可以不同，每个代表氢、卤素、C 1-6 烷基或类似物；R 8 代表氢或类似物；R 9 代表C 1-6 烷基或类似物；V 1 代表氧或类似物；V 2 代表氧或硫；W代表—NH—或类似物；X代表—CH═、氮或类似物；Y代表氧或类似物。]

  公开号：

  US20050277652A1

文献信息

• Novel pyridine Derivative and Pyrimidine Derivative (1)
  申请人：Matsushima Tomohiro

  公开号：US20070270421A1

  公开（公告）日：2007-11-22

  A compound represented by the following formula, a salt thereof or a hydrate of the foregoing has an excellent hepatocyte growth factor receptor (HGFR) inhibitory activity, and exhibits anti-tumor activity, angiogenesis inhibitory activity and cancer metastasis inhibitory activity. [R 1 represents C 1-6 alkyl or the like; R 2 and R 3 represent hydrogen; R 4 , R 5 , R 6 , and R 7 may be the same or different and each represents hydrogen, halogen, C 1-6 alkyl or the like; R 8 represents hydrogen or the like; R 9 represents C 1-6 alkyl or the like; V 1 represents oxygen or the like; V 2 represents oxygen or sulfur; W represents —NH— or the like; X represents —CH═, nitrogen or the like; and Y represents oxygen or the like.]

  以下化合物的公式，其盐或水合物具有出色的肝细胞生长因子受体（HGFR）抑制活性，并表现出抗肿瘤活性，抑制血管生成活性和癌症转移抑制活性。 [其中，R1代表C1-6烷基或类似物; R2和R3代表氢; R4，R5，R6和R7可能相同或不同，每个代表氢，卤素，C1-6烷基或类似物; R8代表氢或类似物; R9代表C1-6烷基或类似物; V1代表氧或类似物; V2代表氧或硫; W代表—NH—或类似物; X代表—CH═、氮或类似物; Y代表氧或类似物。]
• Pyridine derivative and pyrimidine derivative
  申请人：Eisai R&D Management Co., Ltd.

  公开号：US07531532B2

  公开（公告）日：2009-05-12

  A compound represented by the following formula, a salt thereof or a hydrate of the foregoing has an excellent hepatocyte growth factor receptor (HGFR) inhibitory activity, and exhibits anti-tumor activity, angiogenesis inhibitory activity and cancer metastasis inhibitory activity. [R1 represents C1-6 alkyl or the like; R2 and R3 represent hydrogen; R4, R5, R6, and R7 may be the same or different and each represents hydrogen, halogen, C1-6 alkyl or the like; R8 represents hydrogen or the like; R9 represents C1-6 alkyl or the like; V1 represents oxygen or the like; V2 represents oxygen or sulfur; W represents —NH— or the like; X represents —CH═, nitrogen or the like; and Y represents oxygen or the like.]

  以下化合物的公式，其盐或水合物具有出色的肝细胞生长因子受体（HGFR）抑制活性，并表现出抗肿瘤活性、抗血管生成活性和癌症转移抑制活性。【R1代表C1-6烷基或类似物；R2和R3代表氢；R4、R5、R6和R7可以相同也可以不同，每个代表氢、卤素、C1-6烷基或类似物；R8代表氢或类似物；R9代表C1-6烷基或类似物；V1代表氧或类似物；V2代表氧或硫；W代表—NH—或类似物；X代表—CH═、氮或类似物；Y代表氧或类似物。】
• Urea Derivatives as Kinase Inhibitors
  申请人：Zhang Dawei

  公开号：US20120077851A1

  公开（公告）日：2012-03-29

  The present invention is directed to novel ureas, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof which are useful for the treatment of protein kinases mediated diseases and conditions. The compounds of this invention have a general Formula (I) wherein R, R 1 to R 10 are defined herein.

  本发明涉及新型脲化合物及其衍生物、药用可接受的盐、溶剂化合物和水合物，这些化合物对蛋白激酶介导的疾病和病状具有治疗作用。本发明的化合物具有一般式(I)，其中R、R1到R10在此定义。
• NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (2)
  申请人：Eisai Co., Ltd.

  公开号：EP1719763A1

  公开（公告）日：2006-11-08

  A compound represented by the following formula, a salt thereof or a hydrate of the foregoing has an excellent hepatocyte growth factor receptor (HGFR) inhibitory activity, and exhibits anti-tumor activity, angiogenesis inhibitory activity and cancer metastasis inhibitory activity. [R1 represents C1-6 alkyl or the like; R2 and R3 represent hydrogen; R4, R5, R6, and R7 may be the same or different and each represents hydrogen, halogen, C1-6 alkyl or the like; R8 represents hydrogen or the like; R9b represents a 3- to 10-memberd non-aromatic heterocyclic group or the like; V1 represents oxygen or the like; V2 represents oxygen or sulfur; W represents -CH2- or the like; X represents -CH=, nitrogen or the like; and Y represents oxygen or the like.]

  下式代表的化合物、其盐或前述化合物的水合物具有极佳的肝细胞生长因子受体（HGFR）抑制活性，并具有抗肿瘤活性、血管生成抑制活性和癌症转移抑制活性。 [R1 代表 C1-6 烷基或类似物；R2 和 R3 代表氢； R4、R5、R6 和 R7 可以相同或不同，各自代表氢、卤素、C1-6 烷基或类似物；R8 代表氢或类似物；R9b 代表 3 至 10 个成员的非芳香杂环基团或类似物；V1 代表氧或类似物；V2 代表氧或硫；W 代表 -CH2- 或类似物；X 代表 -CH=、氮或类似物；Y 代表氧或类似物。］
• NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (1)
  申请人：Eisai R&D Management Co., Ltd.

  公开号：EP1719762B1

  公开（公告）日：2012-06-27